AP-III-a4, also known as ENOblock, is primarily used in research settings to study its effects on cellular metabolism and cancer biology. It acts as an enolase inhibitor, which allows scientists to investigate the role of glycolysis in cancer cells, as enolase is a key enzyme in this metabolic pathway. By blocking enolase, researchers can explore potential therapeutic strategies for targeting cancer metabolism. Additionally, ENOblock has been studied for its potential anti-inflammatory properties, making it a candidate for research in inflammatory diseases. Its ability to modulate metabolic pathways also opens avenues for studying metabolic disorders and neurodegenerative diseases. Overall, ENOblock serves as a valuable tool in understanding the complex interplay between metabolism, disease progression, and potential treatment options.